Abacavir/Lamivudine (Epzicom, Kivexa)
- A Clinical Overview of Abacavir/Lamivudine (Epzicom, Kivexa) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health - GlaxoSmithKline Announces New Program to Provide Financial Assistance for Eligible HIV Patients in the U.S. (November 11, 2008)
Program reduces out-of-pocket expense burden for eligible patients on GSK HIV medications.
From GlaxoSmithKline - What's New in the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents (November 3, 2008)
From AIDSinfo - Prescribing Information for Abacavir/Lamivudine (Epzicom, Kivexa) (PDF) (September 2007)
From GlaxoSmithKline - Switch Studies (SWEET and BICOMBO) Explore Metabolic Issues (July 25, 2007)
In The 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO - The Once-Daily Abacavir/Lamivudine Co-Formulation Proves Its Mettle by Being Both Safe and Effective (September 30, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy - Adverse Event Risk on Abacavir + Lamivudine Is Not Higher for Patients Coinfected With Hepatitis B and/or Hepatitis C (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment - Fixed-Dose Pill of Abacavir/Lamivudine Taken Once a Day Is Comparable to Twice-a-Day Abacavir + Lamivudine (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Understanding Two New Once-a-Day Combinations: Truvada and Epzicom (November/December 2004)
Daniel S. Berger, M.D., reviews issues of drug concentrations, adherence and resistance.
To read PDF, click here
In Positively Aware, from Test Positive Aware Network - New Fixed-Dose Once-a-Day Starting Regimens: Interview With Cal Cohen, M.D. (October 26, 2004)
A leading AIDS physician looks at the advantages and disadvantages of Epzicom and Truvada for those who are first starting antiretroviral treatment.
In AIDS Treatment News, from AIDS Treatment News - Little Leap: Gilead 2-in-1 Opens Door to Impending One-Pill Triple Combo (October 2004)
Rob Camp reports on the generally underwhelming news of the launch of Truvada and Epzicom.
In TAGline, from Treatment Action Group - FDA Approves Two Combination Pills, Epzicom and Truvada; Comment on Commercial Race to Once-a-Day Nucleosides (August 23, 2004)
The benefits of once-a-day drugs haven't been adequately weighed against their potential risks, writes AIDS advocate John James.
In AIDS Treatment News, from AIDS Treatment News - FDA Approves Gilead, GlaxoSmithKline Fixed-Dose Combination AIDS Drugs (August 3, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Two New Fixed-Dose Combinations Approved (August 2, 2004)
From U.S. Food and Drug Administration - Lamivudine/Abacavir Is an Effective Nucleoside Backbone in Combinations Other Than With Tenofovir (July 13, 2004)
Results suggest that the K65R mutation is behind the failure of this three-drug combination.
In The XV International AIDS Conference, from The Body PRO
Clinical Management
Clinical Management
  |